Dengue type 1 viruses circulating in humans are highly by human antibodies

Proceedings of the National Academy of Sciences of the Unite

116, 227-232

DOI: 10.1073/pnas.1812055115

Citation Report

#	Article	IF	Citations
1	Structural differences between dengue viruses circulating in humans and viruses used for vaccine research. Future Virology, 2019, 14, 379-381.	0.9	0
2	Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?. Human Vaccines and Immunotherapeutics, 2019, 15, 2328-2336.	1.4	14
3	Approaches to Interrogating the Human Memory B-Cell and Memory-Derived Antibody Repertoire Following Dengue Virus Infection. Frontiers in Immunology, 2019, 10, 1276.	2.2	6
4	Chronic Dengue Virus Panencephalitis in a Patient with Progressive Dementia with Extrapyramidal Features. Annals of Neurology, 2019, 86, 695-703.	2.8	24
5	Blockade of dengue virus transmission from viremic blood to Aedes aegypti mosquitoes using human monoclonal antibodies. PLoS Neglected Tropical Diseases, 2019, 13, e0007142.	1.3	2
6	Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. Scientific Reports, 2019, 9, 16258.	1.6	10
7	Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. Journal of Infectious Diseases, 2019, 220, 219-227.	1.9	22
8	Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model. EBioMedicine, 2019, 41, 465-478.	2.7	31
9	Dengue vaccine development: Global and Indian scenarios. International Journal of Infectious Diseases, 2019, 84, S80-S86.	1.5	32
10	Recent advances in understanding dengue. F1000Research, 2019, 8, 1279.	0.8	63
11	Insights from direct studies on human dengue infections. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17-19.	3.3	13
12	Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. Current Opinion in Virology, 2020, 43, 59-70.	2.6	41
13	Use of Animal Models in Studying Roles of Antibodies and Their Secretion Cells in Dengue Vaccine Development. Viruses, 2020, 12, 1261.	1.5	1
14	A Two-Dimensional Affinity Capture and Separation Mini-Platform for the Isolation, Enrichment, and Quantification of Biomarkers and Its Potential Use for Liquid Biopsy. Biomedicines, 2020, 8, 255.	1.4	16
15	Zika virus infection enhances future risk of severe dengue disease. Science, 2020, 369, 1123-1128.	6.0	171
16	Chimeric flavivirus enables evaluation of antibodies against dengue virus envelope protein in vitro and in vivo. Scientific Reports, 2020, 10, 21561.	1.6	5
17	Dengue vaccines: the road to failure or to success?. Human Vaccines and Immunotherapeutics, 2020, 16, 2677-2679.	1.4	1
18	A Step in the Right Direction. Journal of Infectious Diseases, 2020, 222, 712-714.	1.9	0

#	Article	IF	Citations
19	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine, 2020, 12, .	5.8	30
20	Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?. Pathogens, 2020, 9, 470.	1.2	10
21	TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis. Nature Communications, 2020, 11, 3177.	5.8	40
22	Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans. PLoS Neglected Tropical Diseases, 2020, 14, e0008034.	1.3	27
23	Potency and breadth of human primary ZIKV immune sera shows that Zika viruses cluster antigenically as a single serotype. PLoS Neglected Tropical Diseases, 2020, 14, e0008006.	1.3	6
24	Subdominance in Antibody Responses: Implications for Vaccine Development. Microbiology and Molecular Biology Reviews, 2021, 85, .	2.9	9
25	Role of the complement system in antibody-dependent enhancement of flavivirus infections. International Journal of Infectious Diseases, 2021, 103, 404-411.	1.5	17
27	An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency. Scientific Reports, 2021, 11, 12987.	1.6	17
28	Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection. Journal of Clinical Investigation, 2021, 131, .	3.9	22
29	Effect of immature tick-borne encephalitis virus particles on antiviral activity of 5-aminoisoxazole-3-carboxylic acid adamantylmethyl esters. Journal of General Virology, 2021, 102, .	1.3	3
30	Implications of Dengue Virus Maturation on Vaccine Induced Humoral Immunity in Mice. Viruses, 2021, 13, 1843.	1.5	0
31	Dengue Preventive Strategies Through Entomological Control, Vaccination and Biotechnology. , 2021, , 57-69.		0
32	Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection. Cell Host and Microbe, 2021, 29, 13-22.	5.1	24
33	Antigenicity, stability, and reproducibility of Zika reporter virus particlesÂfor long-term applications. PLoS Neglected Tropical Diseases, 2020, 14, e0008730.	1.3	9
34	Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics. ELife, 2019, 8, .	2.8	44
35	Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host and Microbe, 2021, 29, 1634-1648.e5.	5.1	5
38	The Burden of Acute Febrile Illness Attributable to Dengue Virus Infection in Sri Lanka: A Single-Center 2-Year Prospective Cohort Study (2016â€“2019). American Journal of Tropical Medicine and Hygiene, 2022, 106, 160-167.	0.6	2
39	IP-10 and CXCR3 signaling inhibit Zika virus replication in human prostate cells. PLoS ONE, 2020, 15, e0244587.	1.1	3

#	Article	IF	Citations
41	Mammalian animal models for dengue virus infection: a recent overview. Archives of Virology, 2022, 167, 31-44.	0.9	19
42	Impact of structural dynamics on biological functions of flaviviruses. FEBS Journal, 2023, 290, 1973-1985.	2.2	5
43	Identification of acridinedione scaffolds as potential inhibitor of DENVâ€2 C protein: An in silico strategy to combat dengue. Journal of Cellular Biochemistry, 2022, 123, 935-946.	1.2	57
45	Generation of Mature DENVs via Genetic Modification and Directed Evolution. MBio, 2022, 13, e0038622.	1.8	11
46	COVID-19 serum can be cross-reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test. International Journal of Infectious Diseases, 2022, 122, 576-584.	1.5	8
47	â€˜Mix and Matchâ€™ vaccination: Is dengue next?. Vaccine, 2022, 40, 6455-6462.	1.7	0
48	TLR2 axis on peripheral blood mononuclear cells regulates inflammatory responses to non-infectious immature dengue virus particles. PLoS Pathogens, 2022, 18, e1010499.	2.1	1
49	Identification of viral RNA sequences in vampire bats (Desmodus rotundus) from central Mexico. Revista Mexicana De Biodiversidad, 0, 93, e934021.	0.4	0
50	prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	4
51	Dengue determinants: Necessities and challenges for universal dengue vaccine development. Reviews in Medical Virology, 2023, 33, .	3.9	1
52	A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. Nature Communications, 2023, 14, .	5.8	9
58	Zika Virus Vaccines. , 2023, , 1322-1333.e7.		0